Alzheimer disease is a progressive neurodegenerative disorder that impairs memory and mental function. It is the most common form of dementia, accounting for 60–70% of cases, and its prevalence is ...

Though there are four histone deacetylase (HDAC) inhibitors that are FDA approved to treat some forms of lymphoma, there’s less evidence for their efficacy in solid tumors. Now, new findings in mice ...

Checkpoint inhibitors play a critical role in immunotherapy. Unfortunately, they don’t work all the time. For reasons that have been largely unknown, some patients respond to checkpoint inhibitor ...

Pancreatic cancer is one of the deadliest cancers - only about one in eight patients survives five years after diagnosis. Those dismal statistics are in part due to the thick, nearly impenetrable wall ...

The July approval of the histone deacetylase (HDAC) inhibitor Beleodaq (belinostat) marks the third HDAC inhibitor to gain registration in the US and the first in almost five years—all for treating ...

A drug with a past life as a potential anti-cancer agent might someday have a new job as "the pill" for men, new data in mice suggest. In a journal article published Feb. 20 in Proceedings of the ...

Most pancreatic tumors are surrounded by a thick, nearly impenetrable wall of fibrosis— scar tissue—that makes it hard for drugs to access and destroy the cancer cells. Researchers at the Salk ...

Several new immunotherapeutic antibodies that inhibit checkpoint receptors on T cells to restimulate the immune system to target tumors have been approved to treat advanced stage lung cancer and ...

Our understanding of the biology of cancer has undoubtedly improved in the last decade. Although remarkable progress has been achieved in the treatment of cancer, much remains to be learned about the ...

Remetinostat, a topical cream and first-in-class inhibitor of histone deacetylation, showed signs of clinical efficacy in patients with basal cell carcinoma. Remetinostat, a topical cream and first-in ...